SXTP
60 Degrees Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.92
−1.16%Aug 14, 2026, 19:47 UTC
60 Degrees Pharmaceuticals reported its financial results for the second quarter of 2026, with net product revenues increasing approximately 106% to about $208 thousand from about $101 thousand in the same quarter of 2025.
Aug 4, 2026, 00:00 UTC
60 Degrees Pharmaceuticals, Inc. signed a securities purchase agreement for a private placement offering of common stock, pre-funded warrants, and Series A and Series B common warrants, with gross proceeds of approximately $1.0 million.
Jul 8, 2026, 12:01 UTC
60 Degrees Pharmaceuticals announced an exclusive option agreement with Florida State University to develop castanospermine for tick-borne diseases.
Source:Jun 11, 2026, 12:03 UTC
60 Degrees Pharmaceuticals signed an exclusive patent license agreement with Florida State University for non-prescription use of Australian Chestnut Extract as a botanical supplement.
Source: